GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc.

  1. February 09, 2021

    Fed. Circ. Panel Walks Back $235M Skinny Label Ruling

    A Federal Circuit panel on Tuesday vacated its October finding that Teva induced infringement of a patent covering GlaxoSmithKline's drug Coreg to the tune of $235 million and set a new round of oral arguments in the high-profile fight over so-called skinny labels.

  2. February 01, 2021

    GSK Blasts Teva's Rehearing Bid In $235M Verdict Fight

    GlaxoSmithKline has urged the Federal Circuit to reject Teva Pharmaceuticals' bid for the full court to reconsider its decision to revive a jury's $235 million verdict in an induced infringement case over a GSK heart failure drug, telling the court its ruling was a "typical review of a properly instructed jury's verdict."

  3. December 17, 2020

    The 10 Biggest Patent Rulings Of 2020

    Patent Trial and Appeal Board decisions on instituting patent reviews have been front and center in 2020, with the U.S. Supreme Court limiting when they can be appealed and the agency defining how discretion can influence those determinations. Here's a look back at the biggest patent cases of the year.

  4. December 16, 2020

    Generics 'Urgently' Call On Fed. Circ. To Protect Skinny Labels

    The Federal Circuit has turned a "safe harbor" that allows generic-drug makers to sell patent-protected drugs for off-patent uses into "dangerous waters," the generics industry told the full court Wednesday, backing Teva's bid to get the induced infringement case taken up.

  5. December 02, 2020

    Teva Says Fed. Circ. Made Skinny Label Law 'A Dead Letter'

    The Federal Circuit rendered a section of the Hatch-Waxman Act that allows generic-drug makers to sell patent-protected drugs for unpatented uses "a dead letter" when it revived GlaxoSmithKline's $235 million induced infringement verdict, Teva warned the court on Wednesday, petitioning the full court to rehear what it called the Federal Circuit's "most important infringement decision in years."

  6. October 07, 2020

    Generics Worry Fed. Circ. Blew Up 'Routine' Labeling Practice

    The Federal Circuit's recent decision to revive a $235 million induced infringement verdict against Teva has left generic-drug makers scared that they'll be effectively barred from selling patent-protected drugs for approved, off-patent uses.

  7. October 02, 2020

    Split Fed. Circ. Revives GSK's $235M Win Against Teva

    The Federal Circuit on Friday revived a $235 million verdict against Teva Pharmaceuticals for inducing infringement of a patent covering GlaxoSmithKline LLC's heart disease drug Coreg. However, the ruling was accompanied by a scathing dissent from the court's top judge.

  8. September 04, 2019

    Fed. Circ. Judge 'Bewildered' Teva Got $235M Verdict Nixed

    A Federal Circuit judge said Wednesday she was bewildered by how Teva Pharmaceuticals persuaded a Delaware federal judge to overturn a $235 million verdict after a jury found it induced infringement of a GlaxoSmithKline LLC drug used to treat heart disease.